NCT02062281View on ClinicalTrials.gov

Study of Evaluating Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine in Children and Adults

PHASE4CompletedINTERVENTIONAL
Enrollment

2,225

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

January 31, 2014

Conditions
Pneumococcal InfectionInfluenza
Interventions
BIOLOGICAL

23-valent pneumococcal polysaccharide vaccine

Single 0.5ml 23-valent pneumococcal polysaccharide vaccine was administered intramuscularly (IM)

BIOLOGICAL

trivalent influenza vaccine

Single 0.5ml trivalent influenza vaccine was administered IM

BIOLOGICAL

23vPPV+TIV

Single 0.5 ml 23-valent pneumococcal polysaccharide vaccine (23vPPV) and a single 0.5 ml trivalent inactivated influenza vaccine (TIV) were administered IM, in one day.

Trial Locations (1)

212200

Yangzhong Center for Disease Control and Prevention, Zhenjiang

All Listed Sponsors
collaborator

Chengdu Institute of Biological Products Co.,Ltd.

INDUSTRY

collaborator

Shanghai Institute Of Biological Products

INDUSTRY

lead

Jiangsu Province Centers for Disease Control and Prevention

NETWORK

NCT02062281 - Study of Evaluating Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine in Children and Adults | Biotech Hunter | Biotech Hunter